Jefferies analyst Surinder Thind maintains Cognizant Tech Solns (NASDAQ:CTSH) with a Hold and lowers the price target from $78 to $72.
MedMen Reports 55% YoY Increase In Q4 2021 Revenue, Continues 2.0 Growth Plan After Partnering With Tilray And Serruya Private Equity
Cannabis retailer MedMen Enterprises Inc.